Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Chrysalis Investments Limited is a Guernsey-based closed-ended investment company focused on generating long-term capital growth through equity and equity-related investments in innovative, high-growth unquoted and listed companies, primarily in the UK and Europe. Incorporated in Guernsey with registered number 65432, it targets businesses with proven models poised to disrupt large addressable markets across sectors like fintech, insurance technology, and pensions, as exemplified by top holdings such as Starling Bank at 39% of assets, Klarna at 14%, and Smart Pension at 13% as of mid-2025. The company employs a high-conviction strategy, providing flexible capital and advisory support to help portfolio firms transition from growth to profitability while fostering complementary ecosystems. Managed by an experienced team including Richard Watts and Nick Williamson, with G10 Capital Limited as AIFM and Chrysalis Investment Partners LLP as investment adviser, it plays a key role in the growth capital sector by backing transformative enterprises and crystallizing value for shareholders. Launched in 2018, it maintains a portfolio emphasizing sustainability, corporate culture, and long-term success potential.
£0.78
+£0.00 (+0.00%)
EOD Jul 3, 2026
Revenue grew 191.1%, still solid.
Even for strong businesses, today's 4x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
3.5x earnings, 4.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£124M
▲ +191.1% YoY
Net Income (TTM)
£120M
▲ +207.2% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
£98M
▲ +322.3% YoY
Op. Cash Flow (TTM)
£124M
▲ +226.4% YoY
Net Debt
-£47M
Net Cash Position
Cash & Equiv.
£118M
Continue Research
At a P/E of 3.5 and a price-to-free-cash-flow of 4.4, Chrysalis Investments (CHRY.XLON) trades below a two-stage DCF intrinsic value of about £9.15 per share, so at £0.78 the stock looks undervalued (1,066.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Chrysalis Investments scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about £9.15 per share for CHRY.XLON, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around £6.86. At today's £0.78, that puts the stock about 1,066.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Chrysalis Investments scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a solid business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CHRY.XLON currently trades below its estimated intrinsic value and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.